3 completed, 2 unknown, 1 withdrawn. 6 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 6 | Completed 3, Unknown 2, Withdrawn 1 |
Follow Hemolysis: new trials by email Literature Review of Hemolysis trials Research Report on Hemolysis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Immunogenicity and Safety of BBIBP-Corv Coadministered With PPV23 and IIV4 in Hemodialysis Population coadministration, COVID-19 vaccine, IIV4+PPV23 - Hemolysis, COVID-19 | Phase 4 | Unknown | China National Biotec Group Company Limited | 1200 | 2022-08-05 | 2022-08-30 |
| HEMolysis in a Percutaneous Axial Flow LVAD, Effects of Pentoxifylline in a Randomized Controlled Trial Pentoxifylline Oral Product, Placebo - Hemolysis Intravascular, Acute Decompensated Heart Failure | Phase 4 | Withdrawn | Cedars-Sinai Medical Center | 2020-06-01 | 2025-05-31 | |
| Safety and Efficacy of Aspirin in Stroke Patients With Glucose-6-phosphate Dehydrogenase Deficiency (SAST) Aspirin, Clopidogrel - G6PD Deficiency, Stroke | Phase 4 | Unknown | First Affiliated Hospital, Sun Yat-Sen University | 440 | 2020-01-22 | 2022-03-16 |
| Low-Dose Peginterferon and Ribavirin to Treat Chronic Hepatitis C in Patients Infected With HCV Genotype 2 or 3 Peginterferon alfa-2a, Ribavirin - Hepatitis C | Phase 4 | Completed | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 58 | 2003-03-01 | 2013-12-06 |
| Pegylated Interferon and Ribavirin to Treat Chronic Hepatitis C With and Without Kidney Disease Peginterferon alfa-2a with Ribavirin, Peginterferon alfa-2a - Chronic Hepatitis C | Phase 4 | Completed | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 50 | 2001-12-01 | 2013-11-08 |
| Long-Term Therapy With Ribavirin for Chronic Hepatitis C Ribavirin - Chronic Hepatitis C | Phase 4 | Completed | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 50 | 1999-02-12 | 2017-07-02 |
Anemia, Hemolytic (3) · Fibrosis (3) · Hepatitis C (3) · Hepatitis C, Chronic (2) · Hepatitis, Chronic (2) · COVID-19 (1) · Glucosephosphate Dehydrogenase Deficiency (1) · Hepatitis (1) · Ischemic Stroke (1) · Liver Diseases (1) · Neutropenia (1) · Renal Insufficiency (1) · Stroke (1)
Pathologic Processes (6) · Pathological Conditions, Signs and Symptoms (6) · Anemia (4) · Hematologic Diseases (4) · Hemic and Lymphatic Diseases (4) · Infections (4) · RNA Virus Infections (4) · Virus Diseases (4) · Blood-Borne Infections (3) · Communicable Diseases (3) · Digestive System Diseases (3) · Flaviviridae Infections (3) · Hepatitis, Viral, Human (3) · Chronic Disease (2) · Disease Attributes (2)
Ribavirin (3) · peginterferon alfa-2a (2) · Aspirin (1) · COVID-19 Vaccines (1) · Clopidogrel (1)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (3) · Cedars-Sinai Medical Center (1) · China National Biotec Group Company Limited (1) · First Affiliated Hospital, Sun Yat-Sen University (1)
United States (4) · China (2)
Domininc Emerson, MD (1) · Jinsheng Zeng, MD,PhD (1) · Rotman Yaron, MD (1) · Tao Huang (1) · Yaron Rotman, MD (1)